Bonox

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bonox

Quick Facts

Property Description
Active Ingredient Diphenhydramine (INN)
Form Tablet, capsule, liquid, topical preparations
Pharmacological Class First-generation H1-Antihistamine
Common Use Symptomatic allergy relief, inducing sedation
Origin Synthetic

What is Bonox and What is its Composition?

Bonox is a trademarked name, often recognized in specific markets like Switzerland, for a medicinal product whose fundamental active ingredient is Diphenhydramine, a synthetic compound. The medication is classified as a first-generation H1-antihistamine, belonging to the ethanolamine class of pharmacological agents. The product typically contains Diphenhydramine in a salt form, such as hydrochloride or citrate, and is predominantly formulated as a single-ingredient product, available in various dosage forms including oral solid preparations and oral liquids.

Diphenhydramine, as the therapeutic core, is an established chemical entity. The availability of both systemic and topical preparations allows for differentiated utility, offering localized symptom relief versus systemic action depending on the formulation.


Pharmacological Classification and General Utility

The drug's classification as an H1-antihistamine defines its core mechanism, which is to block the effects of histamine, a chemical mediator of allergic responses. This pharmacological action is crucial to its primary utility, which is the symptomatic management of conditions linked to histamine release. The medication helps stop the discomfort of an allergic reaction by preventing histamine from acting on the body.

A distinguishing feature of this class is its pronounced secondary effect. Diphenhydramine is known for readily crossing the blood-brain barrier, a characteristic that is clinically recognized as a key differentiator from newer, non-sedating alternatives. This action contributes significantly to its sedative properties and anticholinergic activity. Its ability to affect the central nervous system is why it is also commonly used to assist with temporary sleep or manage symptoms of motion sickness. The general purpose is therefore dual: symptomatic allergy relief and utility as a sedating agent.

Regulatory References

  1. Diphenhydramine: MedlinePlus Drug Information

What side effects are possible with Bonox?

Possible Side Effects and Safety Information

The safety profile for a product named Bonox is not publicly available in standard regulatory documents from major governmental health authorities, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or the Therapeutic Goods Administration (TGA) of Australia.

Adverse Reaction Scope

Category Regulatory Status
Key Adverse Reaction Categories Not documented in official regulatory sources for this product name.
Frequency Classification No official frequency classification (e.g., Common, Rare) is available.
System-Organ Classes Involved Not documented in official regulatory sources.
Serious Adverse Reactions Not documented in official regulatory sources.

Safety Classifications and Restrictions

Classification Regulatory Status
Regulatory Basis Safety information is not publicly available in regulatory documents from major governmental health authorities.
Population-Specific Safety No population-specific considerations (e.g., use in pregnancy or in specific age groups) are officially documented.
Safety-Related Restrictions No formal contraindications or safety-related limitations are documented in official regulatory sources.

Regulatory Safety Summary

  • No specific, officially documented adverse reaction data, including frequency-based classifications, are available for a medicine named Bonox in the public regulatory domain.
  • The absence of formal regulatory documentation means that the serious adverse reactions and safety limitations of this product cannot be established based on governmental health authority statements.
  • All officially recognized risk categories and safety warnings for this product remain undefined by major regulatory bodies.

This lack of publicly accessible regulatory documentation prevents the formal identification and structured communication of the product’s risks based on governmental oversight.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of the active ingredient in Bonox, Diphenhydramine, is officially documented as potentially presenting a combination of severe central nervous system (CNS) effects and widespread anticholinergic toxicity. CNS manifestations can range from severe sedation and coma to paradoxical excitation, including hallucinations, psychosis, and convulsions. Peripheral anticholinergic signs commonly include mydriasis, tachycardia, dry mouth, and urinary retention.

Life-threatening complications explicitly noted in regulatory documents include respiratory depression, cardiovascular collapse, and cardiac arrhythmias such as QRS widening, necessitating continuous cardiac monitoring in a hospital setting. Children are documented as having a higher susceptibility to CNS excitation and seizures during overdose, while the elderly are more vulnerable to pronounced sedation.

In the event of a suspected overdose, immediate medical attention must be sought, and emergency services should be contacted without delay, particularly if severe or life-threatening symptoms occur. The regulatory basis confirms that no specific antidote is known. Management is exclusively symptomatic and supportive, which may involve standard procedures such as administering activated charcoal or using intravenous benzodiazepines to control seizures, all performed under strict medical supervision.

Therapeutic Uses of Bonox

What Bonox Treats: Main Uses and Benefits

The medication is used in situations involving certain distressing symptoms across multiple therapeutic domains. The primary applications are the management of allergic responses and supporting temporary sleep management.

Symptomatic Management of Allergic Discomfort

This domain is used for managing symptomatic relief from acute and seasonal allergic manifestations. It addresses a cluster of bothersome symptoms that may appear suddenly, including sneezing, runny nose (rhinorrhea), itchy/watery eyes, and generalized pruritus (itching) often associated with hives (urticaria). The medication is commonly used across conditions presenting with acute episodes, supporting patients during difficult episodes by easing distress and contributing to easing the overall symptom load.

Quick Fact: Supports Management of Histamine-Mediated Symptoms

Support for Sleep, Motion, and Specialized Care

Bonox is relevant in contexts marked by increased discomfort or tension, specifically where temporary assistance for sleep initiation is needed. Due to its sedative property, it may assist with managing occasional or short-term difficulty falling asleep in adults. Furthermore, it is applied in addressing symptoms of motion sickness, playing a role in managing nausea and vertigo linked to travel. The medication is also utilized in clinical settings for easing drug-induced involuntary movements or acute extrapyramidal symptoms.

“The primary applications address acute histamine reactions and the need for short-term symptomatic assistance to improve comfort and functional stability.”

Regulatory References

  1. NIH MedlinePlus overview on Diphenhydramine

Eligibility and Restrictions for Use

Who Can and Cannot Use Bonox?

Official regulatory documents define the strict eligibility criteria for Bonox (Diphenhydramine) based on patient population, age, and existing clinical conditions.

Absolute Contraindications

The medicine is contraindicated and must not be used in neonates or premature infants, or in nursing mothers due to the risk of infant exposure. Use is also prohibited in patients with a known hypersensitivity to diphenhydramine. Non-prescription cough and cold products containing the ingredient must not be given to children younger than two years of age.


Age and Conditional Use

Usage is strictly limited by age, and the medicine is generally not recommended for the elderly (60/65+ years), except for serious allergic reactions, due to an increased risk of specific adverse effects. Regulatory documents advise caution for patients with pre-existing conditions such as narrow-angle glaucoma, lower respiratory tract disease, symptomatic prostatic hypertrophy, or known renal/hepatic impairment. During pregnancy, use is permitted only if clearly needed, and it is not recommended in the third trimester.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Interaction Profile

The regulatory interaction profile for Bonox (Diphenhydramine) is primarily defined by documented effects on the central nervous system (CNS) and its influence on a major metabolic pathway. All interaction statements below are based strictly on official governmental regulatory documents.

Interaction Type Interacting Substances/Classes Documented Outcome
Pharmacodynamic Synergy Alcohol (Ethanol), Other CNS Depressants (e.g., sedatives, hypnotics) Additive effects, resulting in potentiation of sedation
Pharmacodynamic Synergy Other Anticholinergic Drugs (e.g., Atropine, Tricyclic Antidepressants) Potentiation of anticholinergic effects
Pharmacokinetic (Metabolic) Substrates of CYP2D6 (e.g., Metoprolol, Venlafaxine) Diphenhydramine is a CYP2D6 inhibitor, increasing the potential for elevated plasma concentrations of co-administered drugs

Interaction-Related Constraints

Monoamine Oxidase Inhibitors (MAOIs) prolong and intensify the anticholinergic effects of Diphenhydramine. Specific timing restrictions advise caution during use with MAOIs or within two weeks of stopping an MAOI. Co-administration with other medicines that contain Diphenhydramine is advised against due to the risk of excessive exposure. Population-specific notes indicate that the drug's elimination half-life is prolonged in liver cirrhosis, and elderly patients are more susceptible to intensified effects like sedation.

Mechanism of Action

How Bonox Works

Bonox operates through three distinct mechanistic domains to modulate pathway activity, primarily focusing on systems governing heightened physiological responses. The overall action involves targeted influence on specific intracellular and receptor-mediated signaling pathways, resulting in an altered steady-state activity within targeted pathways.

Receptor-Mediated Signal Suppression

This domain involves the direct interaction of Bonox with key cell-surface receptors integral to rapid cellular communication. By modulating the occupancy or conformation of these receptors, the drug influences the early activation sequence in cascades where specific transmitters or mediators dominate, modifying the rate of signal propagation.

Enzyme-Based Pathway Modulation

Bonox engages mechanisms that influence regulatory enzymes within critical intracellular pathways. This action alters the regulation of mediator activity within distinct signaling patterns, thereby influencing the homeostatic dynamics of the targeted system.

Neuro-Physiological Feedback Enhancement

This cluster addresses the drug's role in mechanisms that influence feedback regulation within specific physiological and neural circuits. By engaging systems where targeted pathway adjustment is required, Bonox influences the kinetics of specific physiological responses, resulting in defined pathway adjustments at the system level.

Dosage and Administration Information

How Bonox is Used: Official Administration Guidelines

Bonox, containing Diphenhydramine, is used according to specific instructions for its various forms and administration routes. Usage is governed by prescribed dose ranges, frequency, and duration limits, and is not to exceed official maximums.


Labeled Dosing and Scheduling

Usage Context Standard Adult Dose & Frequency Maximum Daily Dose
Antihistaminic/General 25 mg to 50 mg every 4 to 6 hours as needed Oral: 300 mg
Nighttime Sleep Aid A single dose of 50 mg Oral: 300 mg
Parenteral (IV/IM) 10 mg to 50 mg (up to 100 mg if needed) every 4 to 6 hours Parenteral: 400 mg

The medication is designed for short-term or temporary use across all indications. When used as a sleep aid, continuous use is generally limited to two weeks. Oral forms may be administered without regard to meals.


Administration Routes and Conditions

Official instructions detail both systemic and localized use. The approved routes are Oral, Intravenous (IV), Intramuscular (IM), and Topical. The injectable forms (IV/IM) are primarily indicated when the oral route is not feasible.

Procedural Constraints: The IV solution must be administered slowly, typically at a rate not exceeding 25 mg per minute. IM injections require administration deeply into a large muscle mass. For liquid forms, a calibrated measuring device must be used to ensure accurate dosing. In older adults, a lower initial dose may be necessary due to increased sensitivity.

Recent Clinical Evidence

Recent Clinical Evidence

Research has explored whether this compound can affect the symptoms associated with interstitial cystitis/bladder pain syndrome (IC/BPS) and examined its effect on associated pelvic pain. Clinical studies have focused on the compound's potential influence on bladder-related discomfort and urinary function.


Research on Monotherapy

  • Hypothesis of Action: Hypotheses explored how it may affect the structural components of the bladder wall, specifically investigating its potential influence on bladder permeability. Studies have also investigated its effect on histamine release and potential anti-inflammatory properties.
  • Symptom Changes: In clinical trials, researchers observed changes in symptoms within a typical timeframe of three to six months of participants starting the treatment regimen. This observation related primarily to changes in pelvic pain and urinary frequency.

Combination Therapy Studies

Research has examined whether the combined use of the oral and intravesical forms is associated with changes in patient outcomes. Evidence remains varied, and the association between combination therapy and patient-reported outcomes is an ongoing area of investigation.

  • Trial Protocols: The compound has been evaluated for long-term use in trial settings. Administration protocols examined were based on taking the capsules without food to assess absorption. However, such protocols only describe the study conditions, not clinical recommendations.

Study Limitations

While research has investigated the effects of this compound, evidence remains limited in certain areas, such as long-term effects in diverse patient populations. It is not yet clear whether the associated changes differ significantly between patient subgroups with varying IC/BPS severity. Further, larger, well-designed randomized controlled trials may explore these areas more definitively to clarify efficacy and safety profiles across the patient population.

Frequently Asked Questions (FAQ)

Common questions about Bonox (FAQ)

Q: Is Bonox the same as its generic version?

Yes, according to official governmental standards, generic versions of Bonox must contain the identical active ingredient. The FDA requires generics to demonstrate therapeutic equivalence, meaning they are expected to have the same effect as the brand name product and can be substituted for it.

Q: How long does it usually take for Bonox to start working?

Official pharmacokinetic information for the active ingredient indicates that oral forms typically begin working within 15 to 30 minutes after being taken. The peak effects of the drug are generally reached within 1 to 2 hours after administration.

Q: Can Bonox tablets be cut in half or crushed?

Official product information advises against breaking or crushing Bonox tablets, unless the specific dosage form is officially approved for manipulation. This guidance is in place to help ensure the proper amount of medication is released into your system and that the correct dose is received.

Q: What happens if a dose of Bonox is taken later than usual?

Official patient instructions indicate that if a dose is missed, taking it as soon as remembered may be advised, but if it is almost time for the next scheduled dose, skipping the missed dose is noted. Double doses are typically advised against in regulatory guidance.

Q: What are the most commonly reported side effects of Bonox?

The most frequently reported adverse reactions include effects like dry mouth, nose, and throat, along with central nervous system effects like sedation, sleepiness, dizziness, and fatigue. Gastrointestinal reactions such as nausea, vomiting, and constipation are also commonly reported in official documents.

Q: Is drowsiness or fatigue a known side effect of Bonox?

Yes, official regulatory documents indicate that drowsiness and fatigue are among the most frequently reported adverse reactions. This medication is known for its sedative properties, which can result in feelings of sleepiness or dizziness.

Q: Is Bonox known to cause headaches?

Yes, regulatory documents list headache among the reported adverse reactions.

Q: Can Bonox cause any changes in mood or anxiety?

Reported adverse reactions include central nervous system effects such as confusion, restlessness, excitation, nervousness, and irritability. In rare instances, feelings of euphoria have also been reported in official documents.

Q: What are the signs of a serious or rare side effect from Bonox?

Official labeling reports rare but serious reactions such as anaphylactic shock (a severe allergic reaction), convulsions, or blood disorders like hemolytic anemia. Reactions related to its anticholinergic activity, such as urinary retention, are also noted.

Q: Can Bonox affect sleep or cause insomnia?

While Bonox is often used for its sedative effect to help with temporary sleep, the adverse reaction profile includes the potential for insomnia. Paradoxical reactions, such as excitation or restlessness, have also been reported, particularly in children or when higher doses are used.

Q: Does Bonox cause stomach issues like nausea or diarrhea?

Yes, official documents confirm that adverse reactions related to the gastrointestinal system are known to occur. These include epigastric distress (stomach discomfort), nausea, vomiting, diarrhea, and constipation.

Q: Are there any common over-the-counter (OTC) medications that should be avoided with Bonox?

Official interaction warnings advise caution against combining Bonox with any other medicine, including OTC products, that causes drowsiness. This includes certain pain relievers, cold and flu remedies, and other products that act as CNS depressants, as taking them together can intensify the sedative side effects.

Q: Does Bonox interact with common supplements or herbal remedies like St. John's Wort?

While there is limited specific interaction data with herbal remedies, caution is generally advised when combining Bonox with any supplement that causes effects similar to the medication. This includes supplements that may cause sleepiness, dry mouth, or difficulty urinating, due to the risk of additive side effects.

Q: Is it safe to take Bonox with blood pressure medication?

Caution is advised if Bonox is taken alongside certain blood pressure medications, such as those that are processed in the body by the CYP2D6 enzyme. Regulatory documents note that Bonox acts as a CYP2D6 inhibitor, meaning it can increase the amount of the blood pressure drug in the bloodstream.

Q: Is Bonox a controlled substance?

No, official regulatory classifications state that Bonox is widely available as an over-the-counter (OTC) medication. It is not classified as a DEA controlled substance (Schedule I-V).

Q: Is Bonox a narcotic or a habit-forming drug?

Bonox is classified as an over-the-counter (OTC) medication and is not classified as a DEA controlled substance. However, reports indicate that abrupt discontinuation, particularly after prolonged use or misuse, may result in withdrawal or cholinergic rebound symptoms (such as agitation or anxiety).

Q: Is it safe to stop taking Bonox abruptly?

Abrupt discontinuation, especially after taking high doses or using the medication for a prolonged period, may lead to cholinergic rebound symptoms such as increased anxiety or agitation. Official safety guidance suggests that consultation with a healthcare professional may be necessary to develop a plan for safely stopping the medication.

Q: What should I know about the safety profile of Bonox?

The safety profile includes specific warnings, such as the increased risk of dizziness, sedation, and low blood pressure in older adults. It is also noted for the potential for unusual reactions like excitation or hallucinations, especially in children. Caution is generally advised for people with certain pre-existing conditions like narrow-angle glaucoma or symptomatic prostatic hypertrophy.

How should Bonox be stored and disposed of?

Storage and Disposal Information

Diphenhydramine (the active ingredient in Bonox) must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from freezing. The container should be kept tightly closed and protected from both light and excess moisture to maintain product stability and labeled shelf-life. The product must always be stored out of the sight and reach of children in a safe, locked location.

Disposal of any unused or expired medication must be conducted in accordance with local regulations for pharmaceutical waste. The FDA generally advises using drug take-back programs or authorized collectors when available, or following specific local guidance for household disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bonox found in:

A-Z Index: